Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate.
We have previously observed that pyridoxine treatment reduced plasma total cholesterol (TC) and low-density lipoprotein (LDL) cholesterol concentrations and increased antithrombin III (AT III) activity in atherosclerotic patients with subnormal plasma pyridoxal 5-phosphate (PLP) levels. In order to confirm these results, we selected 17 males with low plasma PLP levels from a group of 122 80-year-old males in whom PLP has been determined. After supplementation with 120 mg of pyridoxine per day for 8 weeks their mean plasma TC and LDL cholesterol concentrations were decreased by 10% (p less than 0.01) and 17% (p less than 0.001), respectively. There was no effect on high-density lipoprotein cholesterol and triglycerides but plasma AT III activity was increased by 6% (p less than 0.05). The mechanism by which pyridoxine acts is unclear but it is hypothesized that pyridoxine-derived PLP may enhance the catabolism of LDL and the activity of AT III by inhibiting their glycosylation.
Brattström
L
L
Department of Neurology, University Hospital, Lund, Sweden.
Stavenow
L
L
Galvard
H
H
Nilsson-Ehle
P
P
Berntorp
E
E
Jerntorp
P
P
Elmståhl
S
S
Pessah-Rasmussen
H
H
D000368:Aged; D000369:Aged, 80 and over; D000990:Antithrombin III / Q000032:analysis*; D002784:Cholesterol / Q000097:blood*; D006031:Glycosylation; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D011732:Pyridoxal Phosphate / Q000097:blood*; D011736:Pyridoxine / Q000494:pharmacology*
D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D011732:Pyridoxal Phosphate; D000990:Antithrombin III; D002784:Cholesterol; D011736:Pyridoxine